Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated advanced or unresectable hepatocellular carcinoma in adults.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 2725
Provisional Schedule
- Expected publication:
- 19 August 2025
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- AstraZeneca (durvalumab, tremelimumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- British Liver Trust
- Professional groups
- Association of Cancer Physicians
- British Association of the Study of the Liver (BASL) / HCC UK
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated guideline groups
- NICE - National Guideline Alliance (cancer, mental health, and women and children’s health)
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Eisai (lenvatinib)
- Roche (atezolizumab, bevacizumab)
- Sirtex (SIR-Spheres)
- Evidence review group
- National Institute for Health Research Health Technology Assessment Programme (NETSCC)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 July 2025 - 29 July 2025 | Final draft guidance |
| 09 April 2025 | Committee meeting: 2 |
| 04 February 2025 - 25 February 2025 | Draft guidance |
| 14 January 2025 | Committee meeting |
| 14 January 2025 | Declaration of interests |
| 11 June 2024 | Invitation to participate |
| 08 April 2024 - 06 May 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2725 |
| 28 March 2024 | In progress. Please note that following on from advice received from the company this topic has now been scheduled back into the work programme. We now anticipate that the appraisal will begin during mid-June 2024 when we will write to you about how you can get involved. |
| 22 November 2023 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps. |
| 10 January 2020 | In progress. Referred October 28 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual